Power Law company profile

Nurix

Biotech & Life Sciences · San Francisco, United States · Founded 2012 · IPO 2020 Colt

Develops small molecule inhibitors for the treatment of proliferative and degenerative diseases

Valuation

$1.24B

Market cap · May/2026

Revenue

$84M

Latest reported FY

Featured in $1B+ revenueColt · Power Law growth-stage

Investors

10 investors on Nurix's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 2 investors entered at this stage

The Column Group

Third Rock Ventures

Series B+ 8 investors entered at this stage

Boxer Capital

Foresite Capital

Wellington Management

University of California

Berkeley

Bain Capital Life Sciences

EcoR1 Capital

Redmile Group

Global footprint

Where Nurix has talent and traffic

AI talent share

1.1% of workforce is AI talent
(4 of 350 staff)

Core AI30.86%

Other AI10.29%

Non-AI workforce34698.86%

Workforce by country

🇺🇸 United States · San Francisco HQ

Book a demo for the full country breakdown

Web traffic by country

15K monthly visits
across markets

🇺🇸 United States69.3%

🇮🇳 India18%

🇬🇧 United Kingdom9.3%

🇩🇪 Germany0.7%

Top 4 markets shown

Market sentiment

What the market is saying about Nurix

An AI-synthesized read of the highest-engagement posts about Nurix on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Nurix on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles